臍帯血の幹細胞研究は、自閉症のために有望です

最初の-そのユニークな二重盲検, crossover study of children with autism who were treated with their own cord blood showed the treatment to be safe and suggests improvement in socialization.

The study, which was published this week in the medical journal Stem Cells Translational Medicine, involved 30 children and was conducted by Michael Chez, M.D., the primary investigator who designed the study that was carried out through the Sutter Neuroscience Institute of Sacramento and the Sutter Institute for Medical Research, with research grant funding by Cord Blood Registry® (CBR®). It was the first randomized, double-blinded, placebo-controlled trial performed in the United States to assess the feasibility of treating autistic children by using their own newborn cord blood harvested from their banked umbilical cord.

stem cell therapy autism

One of the most exciting outcomes of the study, said Dr. Chez, who is with Sutter Neuroscience Institute, involved successful treatment and blinding of parents and investigators, and safety and tolerability of the treatment in this autistic patient population. Trends toward improvements in areas such as socialization and language were observed.

The Vineland Adaptive Behavior Scale for Socialization, one of the tests commonly used to measure real-world functional abilities, showed significant improvement after 12 weeks of cord blood treatment over placebo,” 博士. Chez said. しかしながら, when correcting for possible statistical chance when looking at many outcome variables, this observed significance no longer reached significance, probably due to variables such as only 30 patients in this pilot research study.

The study also mirrored a recent non-blinded, open-label Duke University trial that showed similar Vineland Socialization score improvements while also demonstrating that the use of autologous cord blood is safe for the children through intravenous infusions.

Parents contacted about the study were pleased with the improvements they saw in their children.

Jennifer Lundberg of Orlando, フロリダ州。, 生理食塩水とは対照的に、ヘイデンは、臍帯血の点滴を受けたとき、彼女はほとんどすぐに知っていたと述べました.

“私たちは、彼がトイレ訓練を受け持って4年以上のためにしようとしていました, 2週間以内に、彼は自己トイレに開始しました. 私たちは、これが可能だと思ったことはありません,” 彼女は言いました. “彼はまた、今、彼は前に持っていなかったことを言語のこの世界的な理解を持っています. 例えば, 私はエアコンの吹き出し口を開くために彼を求めるだろう, 彼の突然のすべては、何をすべきかを知っていました. 彼は、彼が持っていたのと同じ爆発を持っていません. It is truly amazing. If we could do it again, we definitely would do it again.

Another mother who asked not to be identified said her young son also improved. “We saw improvements in his overall development – in his language and social interaction,” 彼女は言いました. “It definitely helped.

CBR, which funded the study, has long been committed to supporting research on the use of cord blood to treat a variety of diseases from cerebral palsy and autism to hearing loss and Type I diabetes.

The outcome of Dr. Chez’s study, in addition to other recent research advances looking at the use of cord blood for children with autism, are encouraging,” said Heather Brown, vice president of scientific and medical affairs, CBR. “As researchers continue to explore cord blood’s role in regenerative medicine, CBR remains dedicated to investing in clinical trials to better understand this potential and investigating ways we can increase cord blood’s utility.

Sutter Neuroscience Institute and Sutter Institute for Medical Research are affiliates of Sutter Health, Northern California’s largest health provider. Sutter Health was named one of the nation’s top five large health systems in 2016 thanks to its integrated network of physicians, employees and volunteers—more than 60,000 people strong. Rooted in Sutter Health’s not-for-profit mission, these team members partner to deliver exceptional care that feels personal. 医師のオフィスから病院への外来診療センターや家庭サービスへ, 彼らは誇らしげにサポートし、よりから学びます 3 彼らの中に百万人のケア、ほぼ 1 米の割合. 人口, 世界で最も多様で革新的な地域の一つで.

新しい幹細胞療法自閉症

SOURCEサッター健康


NBScience

医薬品開発業務受託機関

幹細胞治療